Inventory

12 Months Ended

Dec. 31, 2023

Inventory Disclosure [Abstract]

Inventory

Inventory

At December 31, 2023 and 2022, the Company’s inventory primarily related to ORLADEYO. Additionally, inventory included RAPIVAB and peramivir, which is manufactured for the Company’s partners.

The Company’s inventories consisted of the following (in thousands):

	December 31,
	2023		2022
Raw materials	$	6,449	$	8,906
Work-in-process	17,591		14,990
Finished goods	6,242		4,814
Total inventory	$	30,282	$	28,710
Reserves	(1,599)		(1,177)
Total inventory, net	$	28,683	$	27,533

During the years ended December 31, 2023 and 2022, the Company evaluated its inventory levels and associated expiration dating relative to the latest sales forecasts for ORLADEYO, RAPIVAB and peramivir and recorded estimated inventory valuation reserves for those inventories at risk of obsolescence.